Characterization of Ceftazidime Resistance in Clinical Isolates of Bacteria in Lahore, Pakistan

Author's: Mehwish Saleem, Ayesha Batool, Muhammad Naeem Iqbal, Asfa Ashraf
Corresponding Author:      Email:
Article Type: Research Article     Published: Oct. 12, 2018 Pages: 44-50
DOI:        Views 244

Abstract:

The aim of the current study was to determine Ceftazidime resistance in clinical isolates of bacteria in Lahore, Pakistan. This study was carried out at Lahore in Pathology Laboratory, Sir Ganga Ram Hospital from January to June 2018. In order to study the Ceftazidime resistant pattern, a total of 190 clinical samples were collected from different patients. From these collected samples exceeding number 88 were of pus samples followed by 56 blood, 25 sputum and 21 urine samples. All clinical samples were subjected to conventional cultural and biochemical methods for microbial enumeration. Antibiotic sensitivity was analyzed using agar disk diffusion method. The results revealed a higher prevalence of clinical samples among females (53.68%), and in age group 0-20 years (67%). Prevalence of bacteria isolated was Escherichia coli (81.57%), followed by Staphylococcus aureus (7.89%), Pseudomonas sp. (4.22%), Klebsiella sp. (3.16%), and Proteus sp. (3.16%). Rate of resistance to Ceftazidime was higher in females than in the males. Teenagers were highly resistant to Ceftazidime. Among the bacterial isolates, higher resistance to Ceftazidime was shown by E.coli (56.31%), followed by S.aureus (6.84%), Pseudomonas sp. (4.21%), Klebsiella sp. (1.57%), and least resistance by Proteus sp. (1.05%). Resistance to Ceftazidime illustrated that more consumption of a specific antibiotic leads to sustainability of resistance against those antibiotics.

Keywords:

Ceftazidime, antibiotic sensitivity, bacteria, Sir Ganga Ram Hospital.

Citation:

Saleem, M., Batool, A., Iqbal, M.N, Ashraf, A., 2018. Characterization of Ceftazidime Resistance in Clinical Isolates of Bacteria in Lahore, Pakistan. Int. J. Mol. Microbiol., 1(2): 44-50.